InMed Pharmaceuticals annual r&d spending
2020
2021
2022
2023
2024
2025
InMed Pharmaceuticals R&D Spending Growth & History (INM)
InMed Pharmaceuticals's r&d spending was $2.9M for fiscal 2025.
View full InMed Pharmaceuticals company overviewInMed Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $2.9M | −$363,597 | −11.30% |
| 2024 | 2024-06-30 | $3.2M | −$514,539 | −13.79% |
| 2023 | 2023-06-30 | $3.7M | $3.7M | +1866027900.00% |
| 2022 | 2022-06-30 | $0.2 | −$5.3M | −100.00% |
| 2021 | 2021-06-30 | $5.3M | −$473,182 | −8.14% |
| 2020 | 2020-06-30 | $5.8M | — | — |
InMed Pharmaceuticals quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $1.0M | $597,260 | +140.41% |
| Q2 2026 | 2025-12-31 | $630,636 | −$264,540 | −29.55% |
| Q1 2026 | 2025-09-30 | $581,612 | −$118,533 | −16.93% |
| Q4 2025 | 2025-06-30 | $833,229 | $174,360 | +26.46% |
| Q3 2025 | 2025-03-31 | $425,370 | −$231,394 | −35.23% |
| Q2 2025 | 2024-12-31 | $895,176 | $285,385 | +46.80% |
| Q1 2025 | 2024-09-30 | $700,145 | −$591,948 | −45.81% |
| Q4 2024 | 2024-06-30 | $658,869 | $35,125 | +5.63% |
| Q3 2024 | 2024-03-31 | $656,764 | −$221,539 | −25.22% |
| Q2 2024 | 2023-12-31 | $609,791 | −$241,565 | −28.37% |
| Q1 2024 | 2023-09-30 | $1.3M | −$86,560 | −6.28% |
| Q4 2023 | 2023-06-30 | $623,744 | — | — |
| Q3 2023 | 2023-03-31 | $878,303 | −$875,242 | −49.91% |
| Q2 2023 | 2022-12-31 | $851,356 | −$1.7M | −66.44% |
| Q1 2023 | 2022-09-30 | $1.4M | −$112,599 | −7.55% |
| Q3 2022 | 2022-03-31 | $1.8M | −$19,048 | −1.07% |
| Q2 2022 | 2021-12-31 | $2.5M | $1.6M | +170.49% |
| Q1 2022 | 2021-09-30 | $1.5M | $580,096 | +63.67% |
| Q4 2021 | 2021-06-30 | $1.7M | $748,777 | +77.38% |
| Q3 2021 | 2021-03-31 | $1.8M | $497,680 | +39.04% |
| Q2 2021 | 2020-12-31 | $937,948 | −$668,883 | −41.63% |
| Q1 2021 | 2020-09-30 | $911,156 | −$1.1M | −53.56% |
| Q4 2020 | 2020-06-30 | $967,610 | — | — |
| Q3 2020 | 2020-03-31 | $1.3M | — | — |
| Q2 2020 | 2019-12-31 | $1.6M | — | — |
| Q1 2020 | 2019-09-30 | $2.0M | — | — |
InMed Pharmaceuticals r&d spending trends
Over the last five fiscal years, InMed Pharmaceuticals's r&d spending decreased from $5.8M to $2.9M, a change of −$3.0M. The latest reported quarter, Q3 2026, shows $1.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review InMed Pharmaceuticals source filings ↗